Frontiers in Oncology, Section “Molecular and Cellular Oncology” |
| Perspectives on Reprograming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies |
| Fabian Benencia, Maria Muccioli, and Mawadda Alnaeeli |
| Targeting PI3K/Akt/mTOR Signaling in Cancer |
| Camillo Porta, Chiara Paglino, and Alessandra Mosca |
| Transcriptional Activity of Heparan Sulfate Biosynthetic Machinery is Specifically Impaired in Benign Prostate Hyperplasia and Prostate Cancer |
| Anastasia V Suhovskih, Aneksandra Y Tsidulko, Olesya S Kutsenko, Anna V Kovner, Svetlana V Aidagulova, Ingemar Ernberg, and Elvira V Grigorieva |
| Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising |
| Christian Robert Jekimovs, Emma Bolderson, Amila Suraweera, Mark Adams, Kenneth John O'Byrne, and Derek John Richard |
| Targeting PI3K/mTOR Signaling in Cancer |
| Alexandre Arcaro |
| Corrigendum: Involvement of a Non-Human Sialic Acid in Human Cancer |
| Annie Nithya Samraj, Heinz Läubli, Nissi Varki, and Ajit Varki |
| Protein Kinase C Beta in the Tumor Microenvironment Promotes Mammary Tumorigenesis |
| Julie A Wallace, Jason R Pitarresi, Nandini Sharma, Marilly Palettas, Maria C Cuitiño, Steven T Sizemore, Lianbo Yu, Allen Sanderlin, Thomas J Rosol, Kamal D. Mehta, Gina M Sizemore, and Michael C Ostrowski |
| Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma |
| Fabio Massaiti Iwamoto and Adilia Hormigo |
| The Role of STAT1 for Crosstalk between Fibroblasts and Colon Cancer Cells |
| Pawan Kaler, Benjamin Y Owusu, Leonard Augenlicht, and Lidija Klampfer |
| Mysteries of TGF-β Paradox in Benign and Malignant Cells |
| Chung Lee |
| Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers |
| C Elizabeth Caldon |
| Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment |
| Mary B Mockler, Melissa Jane Conroy, and Joanne Lysaght |
| The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis |
| Uwe Knippschild, Marc Krüger, Julia Richter, Pengfei Xu, Balbina García-Reyes, Christian Peifer, Jakob Halekotte, Vasiliy Bakulev, and Joachim Bischof |
| Dihydroartemisinin is a Hypoxia-Active Anti-Cancer Drug in Colorectal Carcinoma Cells |
| Teona Ontikatze, Justine Rudner, René Handrick, Claus Belka, and Verena Jendrossek |
|
|
Frontiers in Oncology, Section “Radiation Oncology” |
| Effect of Treatment Modality on the Hypothalamic–Pituitary Function of Patients Treated with Radiation Therapy for Pituitary Adenomas: Hypothalamic Dose and Endocrine Outcomes |
| Andrew Elson, Joseph Bovi, Kawaljeet Kaur, Diana Maas, Grant Sinson, and Chris Schultz |
| The potential role of magnetic resonance spectroscopy in image-guided radiotherapy |
| Mai Lin Nguyen, Brooke Willow, Rihan Khan, Alexander Chi, Lyndon Kim, sherif Nour, Thomas Sroka, Christine Kerr, Juan Godinez, Melissa Mills, ULF LENNART Karlsson, Gabor Altdorfer, Nam Phong Nguyen, and Gordon Jendrasiak |
| Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation |
| Marina Carla Cabrera, Estifanos Tilahun, Rebecca Nakles, Edgar Diaz-Cruz, Aline Charabaty, Simeng Suy, Patrick Jackson, Lisa Ley, Rebecca Slack, Reena Jha, Sean P Collins, Nadim Haddad, Bhaskar V.S. Kallakury, Timm Schroeder, Michael J Pishvaian, and Priscilla A Furth |
Frontiers in Oncology, Section “Surgical Oncology” |
| Laparoscopic and Robotic Total Mesorectal Excision in the Treatment of Rectal Cancer. Brief Review and Personal Remarks |
| Paolo Pietro Bianchi, Wanda Petz, Fabrizio Luca, Roberto Biffi, Giuseppe Spinoglio, and Marco Montorsi |
| Adenocarcinoma Arising from Sacrococcygeal Mature Teratoma in an Adult Female: Report of a Case |
| Naoki Matsumoto, Keisuke Uehara, Masataka Ando, Junki Arimoto, Takehiro Kato, Hayato Nakamura, Tomoki Ebata, and Masato Nagino |
Frontiers in Oncology, Section “Tumor Immunity” |
| The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling |
| Christian Stockmann, Dirk Schadendorf, Ralph Klose, and Iris Helfrich |
| Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation |
| Shashi Ashok Gujar and Patrick Lee |
| Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity |
| Zong Sheng Guo, Zuqiang Liu, and David L Bartlett |
| Sorting Out Pandora’s Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma |
| Oliver Ebert and Jennifer Altomonte |
| Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1 |
| Markus Moehler, Katrin Goepfert, Bernd Heinrich, Caroline Breitbach, Maike Delic, Peter Robert Galle, and Jean Rommelaere |
| Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels |
| Anna M. Leung, Agnes Fermin Lee, Junko Ozao-Choy, Romela Irene Ramos, Omid Hamid, Steven J. O'Day, Myung Shin-Sim, Donald L. Morton, Mark B. Faries, Peter A. Sieling, and Delphine J Lee |
Frontiers in Oncology, Section “Women's Cancer” |
| Molecular Epigenetics in the Management of Ovarian Cancer: Are We Investigating a Rational Clinical Promise? |
| Ha Nguyen, Tian Geng, and Mandi Murph |
| Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden |
| Khalid Abubaker, Rodney B Luwor, Ruth Escalona, Orla McNally, Michael A Quinn, Erik W Thompson, Jock K Findlay, and Nuzhat Ahmed |
| Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems |
| Paula Cunnea and Euan Alexander Stronach |
| The Role of the Tumor Stroma in Ovarian Cancer |
| Ben Davidson, Claes Trope, and Reuven Reich |
|
